---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-009490"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:31:33.899933+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# X4 Pharmaceuticals gets second Nasdaq compliance period until Aug 11, 2025 for bid price rule

## Summary
- Closing bid price of XFOR common stock below $1 for 32 consecutive business days as of Aug 13, 2024.
- Initial 180-day compliance period ended Feb 10, 2025; Nasdaq granted additional 180 days to Aug 11, 2025.
- Company may effect a reverse stock split to regain compliance if necessary.
- Failure to comply by Aug 11, 2025 may lead to delisting and an appeal process.

## SEC filing metadata
- accession: 0001628280-25-009490
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828025009490/0001628280-25-009490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828025009490/xfor-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-009490
- JSON: https://secwatch.observer/filing/0001628280-25-009490.json
- Plain text: https://secwatch.observer/filing/0001628280-25-009490.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.